AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20199009 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% applied 30 minutes before surgery
Number of subjects: 100
Study 20199009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brimonidine tartrate)
Number of subjects: 100
Study 17571945 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day lycopene (Lyc-O-Mato) plus a multivitamin
Number of subjects: 81
Study 17571945 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin only
Number of subjects: 81
Study 16263177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 94
Study 16263177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus IPT
Number of subjects: 94
Study 16263177 — intervention group
Group type: COMPARATOR
Intervention: IPT
Number of subjects: 94
Study 16263177 — intervention group
Group type: COMPARATOR
Intervention: BSP
Number of subjects: 94
Study 12297174 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sternal wires (Group I)
Number of subjects: 1000
Study 12297174 — intervention group
Group type: COMPARATOR
Intervention: Thermoreactive Nitillium clips (Group II)
Number of subjects: 1000
Study 10417583 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% kojic acid in a gel containing 10% glycolic acid and 2% hydroquinone
Number of subjects: 40
Study 10417583 — intervention group
Group type: COMPARATOR
Intervention: Gel without kojic acid (control)
Number of subjects: 40
Study 7570132 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine sulphate in 20 ml saline (Group A)
Number of subjects: 40
Study 7570132 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.25% bupivacaine (Group B)
Number of subjects: 40
Study 7570132 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine sulphate in 20 ml of 0.25% bupivacaine (Group C)
Number of subjects: 40
Study 7570132 — intervention group
Group type: COMPARATOR
Intervention: No intra-articular injection (Group D)
Number of subjects: 40
Study 2187555 — intervention group
Group type: EXPERIMENTAL
Intervention: Greasy tulle dressing
Number of subjects: 0
Study 2187555 — intervention group
Group type: COMPARATOR
Intervention: Tincture of benzoin dressing
Number of subjects: 0
Study 2187555 — intervention group
Group type: COMPARATOR
Intervention: Paraffin tulle dressing
Number of subjects: 0
Study 2187555 — intervention group
Group type: COMPARATOR
Intervention: Soframycin addition to greasy tulle
Number of subjects: 0
Study 7400107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (20 mg once daily)
Number of subjects: 30
Study 7400107 — intervention group
Group type: COMPARATOR
Intervention: Standard methylphenidate (10 mg twice daily)
Number of subjects: 30
Study 29691998 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAR treatment arms
Number of subjects: 755
Study 29691998 — intervention group
Group type: EXPERIMENTAL
Intervention: RACAT treatment arms
Number of subjects: 755
Study 29691998 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAR treatment response
Number of subjects: 755
Study 29691998 — intervention group
Group type: EXPERIMENTAL
Intervention: RACAT treatment response
Number of subjects: 755
Study 29691998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AEs
Number of subjects: 755
Study 28177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 1287
Study 28177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment for chronic pain
Number of subjects: 1287
Study 28177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed drugs for pain relief
Number of subjects: 1287
Study 28177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicit drugs for pain relief
Number of subjects: 1287
Study 26112662 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-focused parent group
Number of subjects: 62
Study 26112662 — intervention group
Group type: COMPARATOR
Intervention: Home visiting
Number of subjects: 62
Study 22718298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber transcystic biliary drainage (TBD)
Number of subjects: 248
Study 22718298 — intervention group
Group type: COMPARATOR
Intervention: Standard silicone T-tube (TT)
Number of subjects: 248
Study 20923790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil
Number of subjects: 65
Study 20923790 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate (MgSO₄)
Number of subjects: 65
Study 19568178 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg LDECA
Number of subjects: 24
Study 19568178 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg LDECA plus 30 mg lansoprazole
Number of subjects: 24
Study 17301218 — intervention group
Group type: EXPERIMENTAL
Intervention: Env(+) infants
Number of subjects: 0
Study 17301218 — intervention group
Group type: COMPARATOR
Intervention: Env(-) infants
Number of subjects: 0
Study 15488799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape
Number of subjects: 10
Study 15488799 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 10
Study 11238494 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T(4) therapy
Number of subjects: 20
Study 11238494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11238494 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 20
Study 9894371 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks, then 400 micrograms nocte for 12 weeks)
Number of subjects: 682
Study 9894371 — intervention group
Group type: COMPARATOR
Intervention: Static dose (SD) budesonide (400 micrograms nocte for 18 weeks)
Number of subjects: 682
Study 9894371 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks)
Number of subjects: 682
Study 8115156 — intervention group
Group type: EXPERIMENTAL
Intervention: ProCell (DexSol with hEGF 10 ng/ml and insulin 10 micrograms/ml)
Number of subjects: 105
Study 8115156 — intervention group
Group type: COMPARATOR
Intervention: DexSol (control group)
Number of subjects: 105
Study 8115156 — intervention group
Group type: EXPERIMENTAL
Intervention: ProCell (DexSol with hEGF and insulin)
Number of subjects: 105
Study 2192194 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 17
Study 2192194 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 17
Study 2192194 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 17
Study 656353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine phenylephrine provocative test
Number of subjects: 68
Study 656353 — intervention group
Group type: COMPARATOR
Intervention: Dummy provocative test
Number of subjects: 68
Study 656353 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral iridectomy followed by reprovocation
Number of subjects: 68
Study 30971516 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics predictive model
Number of subjects: 160
Study 28655801 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBirth Program (coaching-based implementation of the WHO Safe Childbirth Checklist)
Number of subjects: 0
Study 25867399 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic duct ligation
Number of subjects: 74
Study 25867399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thoracic duct ligation)
Number of subjects: 74
Study 23602310 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized brain exercise program (Brain Fitness, Dakim Inc.) used 5 days a week for 20-25 minutes each day
Number of subjects: 69
Study 23602310 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 69
Study 23602310 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants playing at least 40 sessions over 6 months
Number of subjects: 69
Study 21900193 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bortezomib induction followed by bortezomib-based maintenance
Number of subjects: 232
Study 18769382 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced kangaroo mother care (KMC) with rocking, singing, and sucking
Number of subjects: 90
Study 18769382 — intervention group
Group type: COMPARATOR
Intervention: Simple kangaroo mother care (KMC) without additional stimulation
Number of subjects: 90
Study 17299078 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 9
Study 15341437 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy (specific type and dosage not detailed)
Number of subjects: 21
Study 15341437 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 21
Study 11686214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rome II criteria
Number of subjects: 2000
Study 11686214 — intervention group
Group type: EXPERIMENTAL
Intervention: Manning criteria
Number of subjects: 2000
Study 11686214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rome I criteria
Number of subjects: 2000
Study 11686214 — intervention group
Group type: EXPERIMENTAL
Intervention: Drossman criteria
Number of subjects: 2000
Study 11686214 — intervention group
Group type: EXPERIMENTAL
Intervention: Talley criteria
Number of subjects: 2000
Study 11686214 — intervention group
Group type: EXPERIMENTAL
Intervention: Kay & Jorgensen criteria
Number of subjects: 2000
Study 9692272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/24 h for the first 6 months)
Number of subjects: 112
Study 9692272 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (control group)
Number of subjects: 112
Study 7870278 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+CD45RA+ (T) lymphocytes
Number of subjects: 9
Study 7870278 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19+CD5+ (B) lymphocytes
Number of subjects: 9
Study 2653554 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline at 25 mg/day
Number of subjects: 58
Study 2653554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31012599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation (NSI) daily for 12 weeks
Number of subjects: 20
Study 31012599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NSI)
Number of subjects: 20
Study 30860117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 19
Study 30860117 — intervention group
Group type: COMPARATOR
Intervention: Saline as placebo (Group C)
Number of subjects: 19
Study 29188890 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberian cured-ham (ICH) enriched ad libitum diet
Number of subjects: 102
Study 29188890 — intervention group
Group type: COMPARATOR
Intervention: Control group (ad libitum diet without ICH)
Number of subjects: 102
Study 24519403 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 54
Study 24519403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23549225 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30-90 mg for 12 weeks)
Number of subjects: 95
Study 23549225 — intervention group
Group type: COMPARATOR
Intervention: Routine ischemic stroke therapy (Control)
Number of subjects: 95
Study 21720661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% + tazarotene cream 0.1%
Number of subjects: 171
Study 21720661 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene cream 0.1%
Number of subjects: 171
Study 19696119 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch intervention (experimental leg)
Number of subjects: 30
Study 19696119 — intervention group
Group type: COMPARATOR
Intervention: No-stretch intervention (control leg)
Number of subjects: 30
Study 16488295 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose UVA1 (20 J/cm2)
Number of subjects: 64
Study 16488295 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose UVA1 (50 J/cm2)
Number of subjects: 64
Study 16488295 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB
Number of subjects: 64
Study 15605686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac applied at a therapeutic dose of 60 mg/100 cm2 3 times daily for 4 days with occlusion for 4 hours.
Number of subjects: 6
Study 15605686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac applied at a single dose of 300 mg/100 cm2 without occlusion.
Number of subjects: 6
Study 11089744 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 0 (ZEEP)
Number of subjects: 10
Study 11089744 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 5 cm H2O
Number of subjects: 10
Study 11089744 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 10 cm H2O
Number of subjects: 10
Study 11089744 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 15 cm H2O
Number of subjects: 10
Study 9093253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free mixture
Number of subjects: 15
Study 9093253 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced mixture
Number of subjects: 15
Study 8462386 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (initial dose: 12.5 mg daily, increased according to tolerance)
Number of subjects: 26
Study 8462386 — intervention group
Group type: COMPARATOR
Intervention: Untreated (Control Group B)
Number of subjects: 26
Study 2939220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg twice daily for 15 days, then 40 mg twice daily for 75 days)
Number of subjects: 30
Study 2939220 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg twice daily for 90 days)
Number of subjects: 30
Study 29648488 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week conductive education (CE) course(s) followed by conventional practice
Number of subjects: 21
Study 29648488 — intervention group
Group type: COMPARATOR
Intervention: 4-month waiting list including conventional practice followed by CE courses
Number of subjects: 21
Study 29756876 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning combined with random structure searching (RSS) algorithms for constructing interatomic potential for boron.
Number of subjects: 0
Study 27458223 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with tenofovir
Number of subjects: 0
Study 27458223 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with efavirenz
Number of subjects: 0
Study 27458223 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with Kaletra (lopinavir/ritonavir)
Number of subjects: 0
Study 27458223 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with ethambutol plus Rifater (rifampin, pyrazinamide, isoniazid)
Number of subjects: 0
Study 27458223 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid
Number of subjects: 0
Study 25275368 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (propofol or sevoflurane)
Number of subjects: 224
Study 25275368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (increased end-tidal pressure by 4 and 8 mmHg during anesthesia)
Number of subjects: 224
Study 22695168 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mm heel lifts (12HL)
Number of subjects: 10
Study 22695168 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mm heel lifts (18HL)
Number of subjects: 10
Study 22695168 — intervention group
Group type: COMPARATOR
Intervention: No heel lifts (NHL)
Number of subjects: 10
Study 20014137 — intervention group
Group type: EXPERIMENTAL
Intervention: VUS-CEUS
Number of subjects: 50
Study 20014137 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 50
Study 18272893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 610
Study 18272893 — intervention group
Group type: COMPARATOR
Intervention: Intubation
Number of subjects: 610
Study 15963379 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reproduction trial with capital letters or abstract shapes; patients performed as proficiently as healthy subjects.
Number of subjects: 0
Study 15963379 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reproduction trial with capital letters; patients failed.
Number of subjects: 0
Study 15963379 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reproduction trial with random shapes; patients did not fail.
Number of subjects: 0
Study 15198156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (75 mg bupivacaine heavy + 50 microg fentanyl)
Number of subjects: 77
Study 15198156 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (15 mg bupivacaine heavy + 50 microg fentanyl)
Number of subjects: 77
Study 15198156 — intervention group
Group type: EXPERIMENTAL
Intervention: Saddle blockade (10 mg bupivacaine heavy + 50 microg fentanyl)
Number of subjects: 77
Study 15198156 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study 10578977 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoView prototype PT system
Number of subjects: 0
Study 10578977 — intervention group
Group type: COMPARATOR
Intervention: Traditional glass slide PT format
Number of subjects: 0
Study 8566268 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified FSH and flare‐up GnRH‐a (Group B)
Number of subjects: 40
Study 8566268 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified FSH and long GnRH‐a (Group C)
Number of subjects: 40
Study 8566268 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and long GnRH‐a (Group D)
Number of subjects: 40
Study 8566268 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified FSH only (Group A)
Number of subjects: 40
Study 1763794 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 104
Study 1763794 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 104
Study 6347154 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 52
Study 6347154 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant immunotherapy)
Number of subjects: 52
Study 30952568 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised psychosocial intervention (comprising a flexible toolkit of psychological-change methods, including contingency management to reinforce abstinence, recovery activities, and clinic attendance)
Number of subjects: 273
Study 30952568 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 273
Study 30952568 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised psychosocial intervention
Number of subjects: 273
Study 30116859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine treatment
Number of subjects: 54
Study 30116859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26909799 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/d
Number of subjects: 71
Study 26909799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 24399647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (0.5‐0.8 milliequivalents per liter)
Number of subjects: 62
Study 24399647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22646475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) prophylaxis during pregnancy
Number of subjects: 100
Study 22646475 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-elicitation using a visual analog scale (feeling thermometer)
Number of subjects: 100
Study 22646475 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability trade-off exercise
Number of subjects: 100
Study 22646475 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized decision analysis
Number of subjects: 100
Study 19607731 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP3 malaria vaccine (15 microg)
Number of subjects: 45
Study 19607731 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP3 malaria vaccine (30 microg)
Number of subjects: 45
Study 19607731 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Engerix B)
Number of subjects: 45
Study 17688074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (MUSE) 250, 500, or 1000 microg, applied three times
Number of subjects: 314
Study 17688074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (MUSE)
Number of subjects: 314
Study 15333080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac repair
Number of subjects: 14
Study 15333080 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 14
Study 11588417 — intervention group
Group type: EXPERIMENTAL
Intervention: Chen Medium
Number of subjects: 32
Study 11588417 — intervention group
Group type: COMPARATOR
Intervention: Optisol-GS
Number of subjects: 32
Study 11588417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both media
Number of subjects: 32
Study 9825420 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshop for community pharmacy personnel
Number of subjects: 492
Study 9825420 — intervention group
Group type: COMPARATOR
Intervention: Intervention customers
Number of subjects: 492
Study 7852065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine sulfate (morphine)
Number of subjects: 80
Study 7852065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine and subfascial angiocatheter lidocaine hydrochloride (lidocaine)
Number of subjects: 80
Study 7852065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine and subfascial angiocatheter normal saline solution
Number of subjects: 80
Study 7852065 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial angiocatheter lidocaine
Number of subjects: 80
Study 2685362 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories (50 mg every 8 hours)
Number of subjects: 41
Study 2685362 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 41
Study 2685362 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories
Number of subjects: 41
Study 31189334 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (hard palate closure at 12 months)
Number of subjects: 143
Study 31189334 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (hard palate closure at 36 months)
Number of subjects: 143
Study 31189334 — intervention group
Group type: COMPARATOR
Intervention: Reference data from peers without cleft palate (CP)
Number of subjects: 143